Brief: Vertex Pharmaceuticals Posts Q1 Adjusted EPS Of $4.06
05/05/2025 21:02
May 5 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O: VERTEX PHARMACEUTICALS Q1 ADJUSTED EPS $4.06 VERSUS IBES ESTIMATE $4.32 VERTEX PHARMACEUTICALS Q1 TOTAL REVENUE $2.77 BILLION VERSUS IBES ESTIMATE $2.85 BILLION VERTEX PHARMACEUTICALS OUTLOOK 2025 TOTAL REVENUE $11.85 BILLION TO $12.0 BILLION VERSUS IBES ESTIMATE OF $11.97 BILLION VERTEX PHARMACEUTICALS: 2025 GUIDANCE INCLUDES AN IMMATERIAL COST IMPACT FROM TARIFFS VERTEX PHARMACEUTICALS: INTANGIBLE ASSET IMPAIRMENT CHARGE OF $379.0 MILLION ASSOCIATED WITH VX-264 IN Q1 Further company coverage: VRTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31